Suppl. Table S1. Clinical and demographic information

|  |  |  |
| --- | --- | --- |
|  | ROSz (*n*=105)Mean (*s.d.*) | CSz (*n*=176)Mean (*s.d.*) |
| Age (years) | 22.1 (3.7)a | 44.0 (11.2) |
| Education (years) | 12.6 (1.9) | 12.4 (2.4) |
| Illness chronicity (years) | 0.5 (0.4)a | 19.5 (11.0) |
| BPRS total | 37.7 (9.3)a | 47.3 (13.6) |
| Positive symptoms | 5.7 (2.9)a | 7.7 (3.8) |
| Negative symptoms | 5.7 (2.5) | 6.0 (2.6) |
| General symptoms | 26.8 (6.2)a | 33.6 (10.8) |
| Antipsychotic medication dosing (CPZ equiv.) | 302.7 (127.7)a | 552.3 (374.5) |
|  | *n* (%) | *n* (%) |
| Gender  | 79 male (75.2%) | 134 male (76.1%) |
| Ethnicity |  |  |
|  Hispanic/Latino | 43 (41.0%)a | 11 (6.3%) |
| Race |  |  |
| Caucasian | 57 (54.3%) | 115 (65.3%) |
| African American | 30 (28.6%) | 51 (29.0%) |
| Asian/Pacific Islander | 12 (11.4%)a | 2 (1.1%) |
| Other | 6 (5.7%) | 8 (4.5%) |
| Atypical antipsychotic medication | 105 (100%)a | 146 (83.0%) |
| Anti-parkinsonian medication | 31 (29.5%) | 34 (19.3%) |

Note: ROSz: recent-onset schizophrenia, CSz: chronic schizophrenia, NP: non-psychiatric community comparison sample, BPRS: Brief Psychiatric Rating Scale, CPZ equiv.: chlorpromazine equivalent, aROSz differs from CSz, *p*<0.05.

Suppl. Table S2. Bivariate correlations between MCCB beta version tests (*n*=281)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MCCB Test | 1.  | 2.  | 3.  | 4.  | 5.  | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. | 15. |
| 1. SC | -- |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 2. Fluency | .44† | -- |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 3. TMT | -.58† | -.29† | -- |  |  |  |  |  |  |  |  |  |  |  |  |
| 4. 3-7 CPT | .46† | .31† | -.31† | -- |  |  |  |  |  |  |  |  |  |  |  |
| 5. CPT-IP | .53† | .36† | -.34† | .69† | -- |  |  |  |  |  |  |  |  |  |  |
| 6. DS | .53† | .35† | -.44† | .47† | .59† | -- |  |  |  |  |  |  |  |  |  |
| 7. LNS | .55† | .38† | -.43† | .49† | .61† | .77† | -- |  |  |  |  |  |  |  |  |
| 8. SS | .54† | .31† | -.47† | .41† | .42† | .53† | .61† | -- |  |  |  |  |  |  |  |
| 9. HVLT-R | .41† | .40† | -.28† | .42† | .46† | .53† | .55† | .42† | -- |  |  |  |  |  |  |
| 10. DLM | .50† | .24† | -.47† | .31† | .40† | .55† | .60† | .59† | .51† | -- |  |  |  |  |  |
| 11.BVMT-R | .59† | .35† | -.47† | .40† | .37† | .50† | .48† | .54† | .49† | .53† | -- |  |  |  |  |
| 12. SL | .53† | .38† | -.39† | .41† | .47† | .52† | .46† | .43† | .50† | .45† | .53† | -- |  |  |  |
| 13. Mazes | .57† | .21† | -.63† | .23† | .30† | .39† | .40† | .56† | .22† | .45\* | .55† | .34† | -- |  |  |
| 14. BD | .61† | .39† | -.52† | .29† | .41† | .56† | .53† | .59† | .40† | .48† | .63† | .45† | .60† | -- |  |
| 15. ME | .28† | .29† | -.16† | .17† | .28† | .37† | .33† | .27† | .44† | .29† | .23† | .31† | .06 | .25† | -- |
| 16. PE | .22† | .13\* | -.14\* | .14\* | .14\* | .19† | .17† | .20† | .18† | .28† | .28† | .27† | .16\* | .24† | .29† |

Note: \*p<0.05, †p<0.01, SC: BACS Symbol Coding, Fluency: Category Fluency, TMT: Trail Making Test A, 3-7 CPT: 3-7 Continuous Performance Test, CPT-IP: Continuous Performance Test, Identical Pairs, DS: BACS Digit Sequencing, LNS: Maryland Letter-Number Span, SS: WAIS-III Spatial Span, HVLT-R: Hopkins Verbal Learning Test – Revised, DLM: NAB Daily Living Memory, BVMT-R: Benton Verbal Memory Test – Revised, SL: NAB Shape Learning, Mazes: NAB Mazes, BD: WAIS-III Block Design, ME: MSCEIT Managing Emotions, PE: MSCEIT Perceiving Emotions.